Tsvetelina Pencheva Hoang
Chief Tech/Sci/R&D Officer at MARKER THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Profile
Tsvetelina Pencheva Hoang is currently the Vice President-Research & Development at Marker Therapeutics, Inc. She previously worked as the Director-Translational Research at Bellicum Pharmaceuticals, Inc. from 2015 to 2018.
Before that, she was a Member at Memorial Sloan Kettering Cancer Center.
From 2013 to 2015, she worked as a Member at The University of Texas M.D.
Anderson Cancer Center.
She also held a position as a Member at The Phi Beta Kappa Society.
Dr. Hoang holds a doctorate degree from The Johns Hopkins University and undergraduate and graduate degrees from Yale University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-02-26 | 0 ( -.--% ) | - $ | 2024-03-30 |
Tsvetelina Pencheva Hoang active positions
| Companies | Position | Start |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-10-22 |
Former positions of Tsvetelina Pencheva Hoang
| Companies | Position | End |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2018-06-30 |
The Phi Beta Kappa Society
 The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services The Phi Beta Kappa Society operates as an organization for liberal arts and science education. The non-profit company is based in Washington. | Corporate Officer/Principal | - |
Training of Tsvetelina Pencheva Hoang
| The Johns Hopkins University | Doctorate Degree |
| Yale University | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
The Phi Beta Kappa Society
The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services The Phi Beta Kappa Society operates as an organization for liberal arts and science education. The non-profit company is based in Washington. | Commercial Services |
- Stock Market
- Insiders
- Tsvetelina Pencheva Hoang